Sponsored by
A completely new approach. I wish them luck. Looks very interesting!
This is a very important trial - hopefully it will allow GBM patients who happen to have the "bad" markers to do as well (or better) than the current standard of care does with GBM patients who have the "good" markers!
Impressive results, but it is on a small group of patients. We need more research on this.
Disclosure: I am on the patient advisory board at Duke.
I love these trials. The main advantage is the lack of side effects of the device. Although it is a nuisance to use - there is no nausea, no messed up blood counts, no pain. I wish them luck on this trial.
This study says that people with high blood sugar have a lower chance of developing a brain tumor. Although it is based on a huge number of patients, there aren't many brain tumor patients so I question the results. I would like to see further research on this - perhaps looking back to previous blood tests on a large group of brain tumor patients and comparing that to historical matched controls who do not have brain tumors.
May be a new target!
Interesting research found a new target in one of the worst forms of pediatric brain cancer, and luckily, found an existing drug that can be used against it. This researcher submitted a grant application to us in our current grant cycle to work on this project. Our National Walk To End Brain Tumors will be raising money for us to give out - If we raise enough money, hopefully we can fund her project and other very promising projects. Go to walktoendbraintumors.org for details on our event!
This treatment is being considered for approval by the USA FDA next week.. I will be speaking there as a patient advocate. Impressive results: Six-month progression-free survival was achieved in 41% of patients receiving GLIOLAN compared to 21% of patients who were operated on without the use of the drug p=0·0003
This is one of my favorite conferences. It is targeted at doctors, researchers and the people who invest in biotech. Not really for patients and families.
It will only be open for a few weeks. If you are thinking of applying, do it now and send it by fax. Do not mail it as you may miss out on it.
This is an exciting trial. An early pilot study showed pretty good results.
Disclaimer: This company is a sponsor of the Musella Foundation
This may be an option when you are told a tumor is inoperable.
Disclosure: this company is a sponsor of the Musella Foundation
This fundraiser gives us 40% of your purchases! Please remember to use this link if you buy Tupperware!
2 announcements from our good friends at the End Brain Cancer Initiative. I have seen Fran Drescher speak at events like this and she is hilarious!
This is a huge advance, although it is a small study and needs to be validated. The concept of a liquid biopsy is that instead of trying to get tumor tissue directly, you get it from blood, or in this case, cerebral spinal fluid, which is a lot easier than brain surgery. You can usually only get a biopsy once or twice of the actual tumor. In some cases, it is dangerous to do a biopsy at all. However, with a liquid biopsy, you can repeat it over time, and see how the tumor is responding to treatment. We are funding the development of a new drug that targets the exact marker this researcher is testing for. I can envision a day when you do this test, and personalize treatment based on it. Then repeat to see how the tumor is trying to mutate around the drug and be able to change the treatment plan.
It is a good sign that they are allowing the trial to go forward!
It is obvious that a gross total resection helps, and this study quantifies it.
This is a dificult article to interpret. I have met this doctor and we went over his research in detail. The results he showed me were pretty good - but nowhere near claiming to be a cure. It was in line with the vaccine trials here in the USA. Some people do very well - others aren't helped at all. I know of a few people doing well on his vaccine. I also know people who weren't heped by it. We recently started tracking his treatment in our virtual trial project but don't have enough data to make a judegement on it yet.
Interesting trial, but it looks like it will only be available in Austrailia for newly diagnosed gbm
This study shows that Optune should be continued after the first recurrence, and use it in addition to a second line therapy. Patients who had a recurrence and remained on Optune therapy did 31% better than those that discontinued Optune.
